Daily Updates
Two More Billion Dollar Deals Show the M&A Wave Has Spread Beyond Big Pharma
The M&A wave is no longer just a big pharma story. Monday brought two more deals, but neither came from the usual mega cap buyers.
The M&A wave is no longer just a big pharma story. Monday brought two more deals, but neither came from the usual mega cap buyers.
Replimune’s RP1 received two complete response letters from the FDA. Two rejections. Most companies would have shelved the program and moved on. Instead, Replimune resubmitted,
If you work in a pharma or biotech lab, you have used Bio Techne products. The recombinant proteins that populate your assay panels. The antibodies
This is the gene therapy story nobody wanted but everybody expected. Sangamo Therapeutics, which pioneered zinc finger nuclease technology and built one of the earliest
Pfizer paid $43 billion for Seagen in 2023 to become an ADC powerhouse. The deal brought in Padcev (bladder cancer), Adcetris (lymphoma), and Tivdak (cervical
AbbVie knows immunology better than almost anyone. Humira made the company more than $200 billion before it went off patent. Skyrizi and Rinvoq are growing
Last Wednesday, Biogen executives told Fierce Biotech the company was becoming “the new Biogen” through external partnerships and acquisitions. Five days later, the company wrote
Moderna’s long-term commercial thesis has always been bigger than COVID. If the mRNA platform can make better flu vaccines, respiratory combination shots, and pandemic-ready constructs,
PwC’s midyear outlook has now put the official stamp on what we have tracked since January: 2026 is a historic dealmaking year. The firm reported
Cisplatin was first approved in 1978. Carboplatin followed in 1989. Nearly fifty years later, these drugs remain standard of care across virtually every solid tumor